Dinani apa kuti muwonetse zikwangwani ZANU patsamba lino ndikulipira kuti mupambane

Waya News

Maphunziro Oyamba Omwe Amayesedwa Poyesa Chithandizo cha OA Knee Pain

Written by mkonzi

Paradigm Biopharmaceuticals Ltd. inanena kuti maphunziro oyambirira adasinthidwa mwachisawawa ndikumwedwa ku United States (US) mu PARA_OA_002 pivotal Clinic trial, kuyesa injectable pentosan polysulfate sodium (PPS/Zilosul®) pofuna kuchiza ululu wokhudzana ndi mafupa a bondo (kOA). ). Phunziro loyamba la randomization linatsimikiziridwa ku Northwestern University, Chicago, ndi Wofufuza Wotsogolera, Dr. Thomas Schnitzer MD, Ph.D.

Kafukufuku wofunikira kwambiri padziko lonse lapansi Phase III, PARA_OA_002, pano akuwunika ndikulembetsa anthu m'malo asanu ndi atatu ku Australia ndipo 21 mwa malo 56 osankhidwa mu US Clinical trial site activation yakhala yofunika kwambiri kwa Paradigm kuyambira kumayambiriro kwa chaka cha kalendala kuti athe dziwe lalikulu la omwe angathe kuzindikiridwa pamasamba omwe atsegulidwa ndikuyamba kuwunika. Kutsegulira masamba ku US kupitilirabe, ndipo masamba aku UK ndi EU akuyambikanso mu CY22.

"Kukhala ndi maphunziro athu oyamba ku US ndichinthu chofunikira kwambiri pa pulogalamu yachipatala ya OA. Gulu lachipatala la Paradigm lakhala likugwira ntchito molimbika kuti ayambitse ndi kuyambitsa masamba ku US, ndipo tikuwona anthu ambiri akulowa gawo lowunika ku US zomwe zidachitika kwa omwe tili nawo," adatero Dr. Donna Skerrett, Chief Medical Officer wa Paradigm komanso CEO wa Interim.

Nkhani Zogwirizana

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Siyani Comment

Gawani ku...